









AMC Swiss Equities


March 5, 2024


Actively Managed Certificate (AMC) invested in Swiss equities. Convictions and bottom-up approach with 20-25 stocks. Opportunistic approach. Investing in SMI and SPI Extra stocks depending on the market cycle and economic cycle. Try to perform with sectors and alpha approach.

Issuer	Société Générale					
Adviser	Heravest SA					
Inception price	100					
Inception date	20.11.2019					
Currency	CHF					
ISIN	CH0507407796					
Liquidity	Daily					
Mgt fees	1.5%					
Price on 04.03.2024	120.1					
# holdings	21					

Top 5 holdings

Logitech	7.7%
UBS	7.2%
VAT Group	7.2%
Novartis	6.5%
Holcim	6.3%





In 2023, Swiss stocks had massively underperformed European and US markets. A rather rare event. Investors took refuge in the Swiss franc, but not in Swiss stocks, preferring the growth character of international stocks, in particular The Magnificent 7. The strength of the Swiss franc had penalized the Swiss stock market, as well as the correlation to US interest rates, high PERs and the weakness of the German economy. See Heravest Weekly 18.12.2023. Nestlé and Roche had recorded poor stock market performances with respectively -7% and -25% for the Roche B and -13% for the Roche PC; their weightings are important in Swiss indices. Swiss stocks have continued to underperform over the first 2 months of 2024. After peaking at 0.925 against the EUR in early January, the Swiss franc fell to 0.96. The Swiss franc broke a support against the EUR. A further decline would be favorable for Swiss equities, mainly those with accounts in CHF. Many Swiss companies are complaining about the rising value of the Swiss franc.

Our portfolio is catching-up with Swiss indices. SLI is the best performer: Nestlé, Roche and Novartis are capped to 9% whereas Nestlé and Roche record negative performance in 2024. Their weightings are close to 15%-20% for the three stocks.

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Year
2024	-1.6%	3.5%	*0.4%										2.2%
2023	10.3%	0.6%	1.8%	-2.8%	-0.6%	-0.1%	-0.4%	-2.1%	-3.4%	-4.0%	7.0%	3.9%	10.7%
2022	-11.0%	-5.2%	1.5%	-3.9%	-3.0%	-6.8%	6.2%	-4.4%	-7.9%	6.2%	3.7%	-3.7%	-26.2%
2021	2.3%	3.5%	3.2%	-0.2%	3.5%	2.2%	2.5%	2.1%	-5.7%	4.3%	0.1%	4.6%	24.2%
2020	-1.0%	-8.6%	-6.1%	7.3%	5.3%	0.4%	0.9%	1.5%	3.0%	-2.4%	11.5%	1.8%	12.7%
2019											1.3%	1.4%	2.7%
*04.03.2024													











Heravest SA

Rue du Cendrier 12-14, 1201 Genève, Suisse www.heravest.com

Philippe Rezzonico Jérôme Baillaud Philippe Schindler

⊠ prezzonico@heravest.com

☑ jbaillaud@heravest.com

□ pschindler@heravest.com

+ 41 22 715 24 42

+ 41 22 715 24 43

+ 41 22 715 24 41

Disclaimer

This document and the information contained or referred therein (the "document") is for informational purposes only. It does not constitute a solicitation, offer or recommendation to buy or sell any securities, collective investments or other financial instrument, to effect any transaction, to implement any particular trading strategy or to conclude any legal act. This document does not provide any investment, legal, accounting or tax advice. It has been prepared without taking into account the objectives, financial situation or needs of any particular investor and does not represent that any products, securities or services discussed are suitable for any investor. Its recipient shall make its own independent decisions whether products, securities or services discussed in this document are appropriate or proper for it based upon its own judgment and upon advice from such advisers as it has deemed necessary.

Any recipient shall independently ensure that it understands the products, securities or services discussed in this document and the risks involved with the avecuation of such transactions. None of Heravest SA or any of its representatives or affiliates shall have any liability what soever for any loss howsoever arising execution of such transactions. None of Heravest SA or any of its representatives or affiliates shall have any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document. Heravest SA does neither represent or warrant the completeness or correctness of this document nor undertake to update the information contained in this document.